N,N-Diethyl-neopentylamin | 17839-29-1

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: N,N-Diethyl-neopentylamin
• 英文别名: Diethylneopentylamine；N,N-diethyl-2,2-dimethylpropan-1-amine
• CAS: 17839-29-1
• 化学式: C₉H₂₁N
• 分子量: 143.272
• InChiKey: TYMAWXRCUDNHPS-UHFFFAOYSA-N

物化性质

• 沸点：
  212-213 °C(Press: 3 Torr)
• 密度：
  1.032 g/cm3

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  10
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  N,N-diethylpivalamide 在 氢气 作用下， 以 乙二醇二甲醚 为溶剂， 160.0 ℃ 、3.0 MPa 条件下， 反应 20.0h， 生成 N,N-Diethyl-neopentylamin
  参考文献：
  名称：

  在温和条件下将酰胺催化加氢为胺

  摘要：

  在（不是很大）压力下：已开发出一种使用双金属Pd-Re催化剂将叔酰胺和仲酰胺氢化成胺的通用方法，具有优异的选择性。反应在低压和较低温度下进行。该方法为有机化学家提供了一种简单可靠的胺合成工具。

  DOI：

  10.1002/anie.201207803

文献信息

• BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT
  申请人：AgeneBio, Inc.

  公开号：US20180170941A1

  公开（公告）日：2018-06-21

  This invention relates to benzodiazepine derivatives, compositions comprising therapeutically effective amounts of those benzodiazepine derivatives and methods of using those derivatives or compositions in treating cognitive impairment associated with central nervous system (CNS) disorders. In particular, it relates to the use of a α5-containing GABA A receptor agonist (e.g., a α5-containing GABA A receptor positive allosteric modulator) as described herein in treating cognitive impairment associated with central nervous system (CNS) disorders in a subject in need or at risk thereof, including, without limitation, subjects having or at risk for age-related cognitive impairment, Mild Cognitive Impairment (MCI), amnestic MCI (aMCI), Age-Associated Memory Impairment (AAMI), Age Related Cognitive Decline (ARCD), dementia, Alzheimer's Disease(AD), prodromal AD, post traumatic stress disorder (PTSD), schizophrenia, bipolar disorder, amyotrophic lateral sclerosis (ALS), cancer-therapy-related cognitive impairment, mental retardation, Parkinson's disease (PD), autism spectrum disorders, fragile X disorder, Rett syndrome, compulsive behavior, and substance addiction. It also relates to the use of a α5-containing GABA A receptor agonist (e.g., a α5-containing GABA A receptor positive allosteric modulator) as described herein in treating brain cancers (including brain tumors, e.g., medulloblastomas), and cognitive impairment associated therewith.

  这项发明涉及苯二氮卓啉衍生物，包括含有这些苯二氮卓啉衍生物的治疗有效量的组合物，以及使用这些衍生物或组合物治疗与中枢神经系统（CNS）疾病相关的认知障碍的方法。具体而言，它涉及在需要或有风险的受试者中治疗与中枢神经系统（CNS）疾病相关的认知障碍，包括但不限于患有或有风险患有与年龄相关的认知障碍、轻度认知障碍（MCI）、遗忘性MCI（aMCI）、年龄相关记忆障碍（AAMI）、年龄相关认知衰退（ARCD）、痴呆症、阿尔茨海默病（AD）、前驱期AD、创伤后应激障碍（PTSD）、精神分裂症、躁郁症、肌萎缩侧索硬化（ALS）、癌症治疗相关认知障碍、智力障碍、帕金森病（PD）、自闭症谱系障碍、脆性X综合症、瑞特综合症、强迫行为和物质成瘾。它还涉及在治疗与之相关的脑癌（包括脑肿瘤，例如髓母细胞瘤）和认知障碍的情况下，如本文所述使用α5含有的GABAA受体激动剂（例如，α5含有的GABAA受体正向变构调节剂）。
• DIHYDROPYRIMIDO LOOP DERIVATIVE AS HBV INHIBITOR
  申请人：MEDSHINE DISCOVERY INC.

  公开号：US20170197986A1

  公开（公告）日：2017-07-13

  Disclosed is a dihydropyrimido fused ring derivative as a HBV inhibitor, and in particular relates to a compound shown as formula (I) or a pharmaceutically acceptable salt thereof.

  本发明公开了一种二氢嘧啶并环衍生物作为HBV抑制剂，特别涉及一种如下式（I）所示的化合物或其药用可接受的盐。
• Aminomethylation of organic halides promoted by zinc in protic medium
  作者：Idália H.S. Estevam、Margarete F. da Silva、Lothar W. Bieber

  DOI：10.1016/j.tetlet.2005.08.139

  日期：2005.10

  halides undergo smooth aminomethylation by secondary amines and aqueous formaldehyde promoted by metallic zinc under copper(I) catalysis. Good to excellent yields are obtained with primary, secondary, and tertiary iodides, allylic, propargylic, and benzylic bromides and with α-bromoesters. In most cases, DMSO is the best solvent, but dioxane is preferable for some more reactive halides. Additional experiments

  在铜（I）催化下，有机卤化物可通过仲胺和甲醛水溶液（由金属锌促进）进行平滑的氨甲基化反应。用伯，仲和叔碘化物，烯丙基，炔丙基和苄基溴化物以及α-溴代酸酯可获得良好或优异的收率。在大多数情况下，DMSO是最好的溶剂，但对于一些更具活性的卤化物，二恶烷是优选的。使用自由基猝灭剂和促进剂的其他实验以及“自由基钟”的使用表明，逐步反应机理是由烷基自由基攻击亚胺离子引发的。
• SUBSTITUTED AZASPIRO DERIVATIVES
  申请人：Xu Yuelian

  公开号：US20080247964A1

  公开（公告）日：2008-10-09

  Substituted azaspiro derivatives of the Formula: are provided, in which variables are as described herein. Such compounds may be used to modulate ligand binding to histamine H3 receptors in vivo or in vitro, and are particularly useful in the treatment of a variety of central nervous system (CNS) and other disorders in humans, domesticated companion animals and livestock animals. Compounds provided herein may be administered alone or in combination with one or more other CNS agents to potentiate the effects of the other CNS agent(s). Pharmaceutical compositions and methods for treating such disorders are provided, as are methods for using such ligands for detecting histamine H3 receptors (e.g., receptor localization studies).

  提供了公式中的替代的azaspiro衍生物，其中变量如本文所述。这些化合物可以用于调节组织胺H3受体在体内或体外的配体结合，并在治疗人类、家养伴侣动物和家畜动物的各种中枢神经系统（CNS）和其他疾病方面特别有用。本文提供的化合物可以单独或与一个或多个其他CNS药剂联合使用，以增强其他CNS药剂的效果。提供了用于治疗这些疾病的药物组合物和方法，以及用于检测组织胺H3受体（例如，受体定位研究）的配体的方法。
• Benzenesulfonyl-Asymmetric Ureas and Medical Uses Thereof
  申请人：HELSINN HEALTHCARE SA

  公开号：US20170275301A1

  公开（公告）日：2017-09-28

  Benzenesulfonyl-asymmetric ureas are provided for the treatment of conditions modulated by the ghrelin receptor.

  苯磺酰基-不对称尿素用于治疗受胃饥饿素受体调节的疾病。